The chief scientific officer of antibody specialist AnaptysBio, Matthew Moyle, has tendered his resignation just over a year after joining the company.

NantCell has paid $13 million up front to work licence CytRx's orphan cancer drug aldoxorubicin.

Researchers have uncovered clues into how a genetic variant raises the risk of migraines, coronary artery disease and other related disorders.

In this week's EuroBiotech Report, AstraZeneca is rocked by Mystic data, GSK culls its pipeline, Bayer posts weak cancer data and more.

The rejig sees Alexion scrapping deals with Moderna Therapeutics, Blueprint Medicines and Arbutus Biopharma as it seeks to focus its R&D.

The Novartis-partnered p53 gene-targeting siRNA cut the rate of acute kidney injury in patients following cardiac surgery.

More biopharma news of note for Thursday.

One of AstraZeneca’s big hopes, a combo of its new I-O med with another experimental cancer drug, has missed a key primary endpoint in first-line lung cancer…

PARP inhibitor Lynparza may be able to kill cancer cells that don’t have BRCA mutations—provided it’s paired with a helper compound.